Obstet Gynecol Sci.  2020 Jul;63(4):417-431. 10.5468/ogs.19169.

Fertility-sparing treatment in early endometrial cancer: current state and future strategies

• Obermair A
• Baxter E
• Brennan DJ
• McAlpine JN
• Muellerer JJ
• Amant F
• van Gent MDJM
• Coleman RL
• Westin SN
• Yates MS
• Krakstad C
• Janda M

• KMID: 2505031
• DOI: http://doi.org/10.5468/ogs.19169

Abstract

Endometrial cancer (EC) is the fifth most common cancer in women worldwide. Global estimates show rising incidence rates in both developed and developing countries. Most women are diagnosed postmenopausal, but 14–25% of patients are premenopausal and 5% are under 40 years of age. Established risk factors include age and hyperestrogenic status associated with nulliparity, obesity, and metabolic syndrome. Standard treatment for EC, which involves total hysterectomy and bilateral salpingo-oophorectomy, has excellent survival outcomes, particularly for low-grade endometrioid tumors. However, it leads to permanent loss of fertility among women who wish to preserve their reproductive potential. With current trends of reproductive-age women delaying childbearing, rising EC incidence rates, and a growing epidemic of obesity, particularly in developed countries, research on conservative non-surgical treatment approaches remains a top priority. Fertility-sparing treatment predominantly involves the use of oral progestins and levonorgestrel-releasing intrauterine devices, which have been shown to be feasible and safe in women with early stage EC and minimal or no myometrial invasion. However, data on the efficacy and safety of conservative management strategies are primarily based on retrospective studies. Randomized clinical trials in younger women and high-risk obese patients are currently underway. Here, we have presented a comprehensive review of the current literature on conservative, fertility-sparing approaches, defining the optimal candidates and evaluating tumor characteristics, reproductive and oncologic outcomes, and ongoing clinical trials. We have also summarized current guidelines and recommendations based on the published literature.

Keyword

Endometrial cancer; Fertility preservation; Conservative treatment; Progestin

Reference

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424.

2. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356–87.

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68:7–30.

4. Trabert B, Wentzensen N, Felix AS, Yang HP, Sherman ME, Brinton LA. Metabolic syndrome and risk of endometrial cancer in the united states: a study in the SEER-medicare linked database. Cancer Epidemiol Biomarkers Prev. 2015; 24:261–7.

5. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2018; 110:354–61.

6. Ota T, Yoshida M, Kimura M, Kinoshita K. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer. 2005; 15:657–62.

7. Duska LR, Garrett A, Rueda BR, Haas J, Chang Y, Fuller AF. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001; 83:388–93.

8. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69:7–34.

9. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15:10–7.

10. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013; 31:2607–18.

11. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006; 95(Suppl 1):S105–43.

12. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005; 366:491–505.

13. Webb PM. Environmental (nongenetic) factors in gynecological cancers: update and future perspectives. Future Oncol. 2015; 11:295–307.

14. Nagle CM, Marquart L, Bain CJ, O'Brien S, Lahmann PH, Quinn M, et al. Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. Eur J Cancer. 2013; 49:2717–26.

15. Hernandez AV, Pasupuleti V, Benites-Zapata VA, Thota P, Deshpande A, Perez-Lopez FR. Insulin resistance and endometrial cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2015; 51:2747–58.

16. Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, et al. Evidence of a causal association between insulinemia and endometrial cancer: a mendelian randomization analysis. J Natl Cancer Inst. 2015; 107:djv178.

17. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016; 387:1094–108.

18. Lajer H, Elnegaard S, Christensen RD, Ortoft G, Schledermann DE, Mogensen O. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey. Acta Obstet Gynecol Scand. 2012; 91:976–82.

19. Lee NK, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007; 109:655–62.

20. Nagle CM, Crosbie EJ, Brand A, Obermair A, Oehler MK, Quinn M, et al. The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer. Gynecol Oncol. 2018; 150:99–105.

21. Ward KK, Shah NR, Saenz CC, McHale MT, Alvarez EA, Plaxe SC. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol. 2012; 126:176–9.

22. American Cancer Society. Surgery for endometrial cancer [Internet]. Atlanta (GA): American Cancer Society;c2017 [cited 2019 Jul 3]. Available from: https://www.cancer.org/cancer/endometrial-cancer/treating/surgery.html.

23. Alonso S, Castellanos T, Lapuente F, Chiva L. Hysteroscopic surgery for conservative management in endometrial cancer: a review of the literature. Ecancermedicalscience. 2015; 9:505.

24. Navarria I, Usel M, Rapiti E, Neyroud-Caspar I, Pelte MF, Bouchardy C, et al. Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment? Gynecol Oncol. 2009; 114:448–51.

25. Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, et al. Gynecologic Cancer InterGroup (GCIG) endometrial cancer clinical trials planning meeting: taking endometrial cancer trials into the translational era. Int J Gynecol Cancer. 2013; 23:1528–34.

26. Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol. 1998; 91:349–54.

27. Matthews TJ, Hamilton BE. Delayed childbearing: more women are having their first child later in life. NCHS Data Brief. 2009; 1–8.

28. Gunderson CC, Java J, Moore KN, Walker JL. The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study. Gynecol Oncol. 2014; 133:23–7.

29. Obermair A, Brennan DJ, Baxter E, Armes JE, Gebski V, Janda M. Surgical safety and personal costs in morbidly obese, multimorbid patients diagnosed with early-stage endometrial cancer having a hysterectomy. Gynecol Oncol Res Pract. 2016; 3:1.

30. Mourits MJ, Bijen CB, Arts HJ, ter Brugge HG, van der Sijde R, Paulsen L, et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol. 2010; 11:763–71.

31. Janda M, Gebski V, Davies LC, Forder P, Brand A, Hogg R, et al. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA. 2017; 317:1224–33.

32. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009; 27:5331–6.

33. Asher R, Obermair A, Janda M, Gebski V. Disease-free and survival outcomes for total laparoscopic hysterectomy compared with total abdominal hysterectomy in early-stage endometrial carcinoma: a meta-analysis. Int J Gynecol Cancer. 2018; 28:529–38.

34. Kondalsamy-Chennakesavan S, Bouman C, De Jong S, Sanday K, Nicklin J, Land R, et al. Clinical audit in gynecological cancer surgery: development of a risk scoring system to predict adverse events. Gynecol Oncol. 2009; 115:329–33.

35. Kondalsamy-Chennakesavan S, Janda M, Gebski V, Baker J, Brand A, Hogg R, et al. Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer. 2012; 48:2155–62.

36. Kondalsamy-Chennakesavan S, Gordon LG, Sanday K, Bouman C, De Jong S, Nicklin J, et al. Hospital costs associated with adverse events in gynecological oncology. Gynecol Oncol. 2011; 121:70–5.

37. Hawkes AL, Quinn M, Gebski V, Armes J, Brennan D, Janda M, et al. Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. Contemp Clin Trials. 2014; 39:14–21.

38. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016; 27:16–41.

39. Leitao MM Jr, Kehoe S, Barakat RR, Alektiar K, Gattoc LP, Rabbitt C, et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol. 2009; 113:105–8.

40. Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 2001; 167:39–48.

41. Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006; 106:804–11.

42. Andreano A, Rechichi G, Rebora P, Sironi S, Valsecchi MG, Galimberti S. MR diffusion imaging for preoperative staging of myometrial invasion in patients with endometrial cancer: a systematic review and meta-analysis. Eur Radiol. 2014; 24:1327–38.

43. Wu LM, Xu JR, Gu HY, Hua J, Haacke EM, Hu J. Predictive value of T2-weighted imaging and contrast-enhanced MR imaging in assessing myometrial invasion in endometrial cancer: a pooled analysis of prospective studies. Eur Radiol. 2013; 23:435–49.

44. Rodríguez-Trujillo A, Martínez-Serrano MJ, MartínezRomán S, Martí C, Buñesch L, Nicolau C, et al. Preoperative assessment of myometrial invasion in endometrial cancer by 3D ultrasound and diffusion-weighted magnetic resonance imaging: a comparative study. Int J Gynecol Cancer. 2016; 26:1105–10.

45. Savelli L, Ceccarini M, Ludovisi M, Fruscella E, De Iaco PA, Salizzoni E, et al. Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging. Ultrasound Obstet Gynecol. 2008; 31:560–6.

46. Kinkel K, Kaji Y, Yu KK, Segal MR, Lu Y, Powell CB, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology. 1999; 212:711–8.

47. Eriksson LS, Lindqvist PG, Flöter Rådestad A, Dueholm M, Fischerova D, Franchi D, et al. Transvaginal ultrasound assessment of myometrial and cervical stromal invasion in women with endometrial cancer: interobserver reproducibility among ultrasound experts and gynecologists. Ultrasound Obstet Gynecol. 2015; 45:476–82.

48. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012; 207:266.e1–266.e12.

49. Gitsch G, Hanzal E, Jensen D, Hacker NF. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol. 1995; 85:504–8.

50. Song T, Seong SJ, Bae DS, Suh DH, Kim DY, Lee KH, et al. Synchronous primary cancers of the endometrium and ovary in young women: a Korean Gynecologic Oncology Group Study. Gynecol Oncol. 2013; 131:624–8.

51. Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005; 106:693–9.

52. Matsuo K, Machida H, Blake EA, Holman LL, Rimel BJ, Roman LD, et al. Trends and outcomes of women with synchronous endometrial and ovarian cancer. Oncotarget. 2018; 9:28757–71.

53. Anglesio MS, Wang YK, Maassen M, Horlings HM, Bashashati A, Senz J, et al. Synchronous endometrial and ovarian carcinomas: evidence of clonality. J Natl Cancer Inst. 2016; 108:djv428.

54. Schultheis AM, Ng CK, De Filippo MR, Piscuoglio S, Macedo GS, Gatius S, et al. Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. J Natl Cancer Inst. 2016; 108:djv427.

55. Li J, Zhu Q, Yang B, Ning C, Liu X, Luo X, et al. Risk factors for ovarian involvement in young and premenopausal endometrioid endometrial cancer patients. Eur J Obstet Gynecol Reprod Biol. 2018; 222:151–4.

56. Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004; 94:456–62.

57. Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol. 2015; 125:89–98.

58. Johnatty SE, Tan YY, Buchanan DD, Bowman M, Walters RJ, Obermair A, et al. Family history of cancer predicts endometrial cancer risk independently of Lynch syndrome: implications for genetic counselling. Gynecol Oncol. 2017; 147:381–7.

59. Sehgal R, Sheahan K, O'Connell PR, Hanly AM, Martin ST, Winter DC. Lynch syndrome: an updated review. Genes (Basel). 2014; 5:497–507.

60. Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011; 305:2304–10.

61. Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, et al. Reply to J. Moline et al. J Clin Oncol. 2014; 32:2278–9.

62. National Comprehensive Cancer Network. NCCN guidelines for patients: uterine neoplasms. Ver 1 [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network;c2019 [cited 2019 Jul 29]. Available from: https://www.nccn.org/patients/guidelines/uterine/.

63. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012; 18:400–7.

64. Spurdle AB, Bowman MA, Shamsani J, Kirk J. Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing. Mod Pathol. 2017; 30:1048–68.

65. Rodolakis A, Biliatis I, Morice P, Reed N, Mangler M, Kesic V, et al. European Society of Gynecological Oncology task force for fertility preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer. 2015; 25:1258–65.

66. Koskas M, Uzan J, Luton D, Rouzier R, Daraï E. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril. 2014; 101:785–94.

67. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012; 125:477–82.

68. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004; 95:133–8.

69. Adlercreutz H, Eriksen PB, Christensen MS. Plasma concentrations of megestrol acetate and medroxyprogesterone acetate after single oral administration to healthy subjects. J Pharm Biomed Anal. 1983; 1:153–62.

70. Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer. 2013; 49:868–74.

71. Park JY, Seong SJ, Kim TJ, Kim JW, Bae DS, Nam JH. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer. Gynecol Oncol. 2017; 146:39–43.

72. Zhang Z, Huang H, Feng F, Wang J, Cheng N. A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer. J Gynecol Oncol. 2019; 30:e61.

73. Minig L, Franchi D, Boveri S, Casadio C, Bocciolone L, Sideri M. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol. 2011; 22:643–9.

74. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999; 17:1736–44.

75. VAN Heertum K, Liu J. Differential effects of progestogens used for menopausal hormone therapy. Clin Obstet Gynecol. 2018; 61:454–62.

76. Yuk JS, Song JY, Lee JH, Park WI, Ahn HS, Kim HJ. Levonorgestrel-releasing intrauterine systems versus oral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy: a meta-analysis. Ann Surg Oncol. 2017; 24:1322–9.

77. Kim MK, Seong SJ, Lee TS, Kim JW, Nam BH, Hong SR, et al. Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009). Jpn J Clin Oncol. 2012; 42:1215–8.

78. Yang B, Xu Y, Zhu Q, Xie L, Shan W, Ning C, et al. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol. 2019; 153:55–62.

79. Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol. 2017; 28:e2.

80. Park JY. Hysteroscopy in fertility-sparing management for early endometrial cancer: a double-edged sword. J Gynecol Oncol. 2017; 28:e16.

81. Kim MK, Seong SJ, Song T, Kim ML, Yoon BS, Jun HS, et al. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer. Gynecol Oncol. 2013; 130:470–3.

82. Park JY, Seong SJ, Kim TJ, Kim JW, Kim SM, Bae DS, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol. 2013; 121:136–42.

83. Chae SH, Shim SH, Lee SJ, Lee JY, Kim SN, Kang SB. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer. Int J Gynecol Cancer. 2019; 29:77–85.

84. Ichinose M, Fujimoto A, Osuga Y, Minaguchi T, Kawana K, Yano T, et al. The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia. Int J Gynecol Cancer. 2013; 23:288–93.

85. Gonthier C, Walker F, Luton D, Yazbeck C, Madelenat P, Koskas M. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer. Gynecol Oncol. 2014; 133:33–7.

86. Chen M, Jin Y, Li Y, Bi Y, Shan Y, Pan L. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Int J Gynaecol Obstet. 2016; 132:34–8.

87. Janda M, McGrath S, Obermair A. Challenges and controversies in the conservative management of uterine and ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2019; 55:93–108.

88. WHO International Agency for Research on Cancer. Population fact sheet: Latin American and the Caribbean 2018 [Internet]. Lyon: WHO International Agency for Research on Cancer;c2018 [cited 2019 Aug 6]. Available from: http://gco.iarc.fr/today/data/factsheets/populations/904-latin-america-and-the-caribbean-factsheets.pdf.

89. World Health Organization. Global status report on noncommunicable diseases 2014 [Internet]. Geneva: World Health Organization;c2014 [cited 2019 Jul 29]. Available from: https://www.who.int/nmh/publications/ncd-status-report-2014/en/.

90. Greenwald ZR, Huang LN, Wissing MD, Franco EL, Gotlieb WH. Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer? Cancer. 2017; 123:1545–54.

91. Kothari R, Seamon L, Cohn D, Fowler J, O'Malley DM. Stage IV endometrial cancer after failed conservative management: a case report. Gynecol Oncol. 2008; 111:579–82.

92. Ferrandina G, Zannoni GF, Gallotta V, Foti E, Mancuso S, Scambia G. Progression of conservatively treated endometrial carcinoma after full term pregnancy: a case report. Gynecol Oncol. 2005; 99:215–7.

93. MacKintosh ML, Derbyshire AE, McVey RJ, Bolton J, Nickkho-Amiry M, Higgins CL, et al. The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk. Int J Cancer. 2019; 144:641–50.

94. Anveden Å, Taube M, Peltonen M, Jacobson P, Andersson-Assarsson JC, Sjöholm K, et al. Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish obese subjects study. Gynecol Oncol. 2017; 145:224–9.

95. Weinberger V, Bednarikova M, Hausnerova J, Ovesna P, Vinklerova P, Minar L, et al. a novel approach to preoperative risk stratification in endometrial cancer: the added value of immunohistochemical markers. Front Oncol. 2019; 9:265.

96. Reijnen C, IntHout J, Massuger LF, Strobbe F, KüstersVandevelde HV, Haldorsen IS, et al. Diagnostic accuracy of clinical biomarkers for preoperative prediction of lymph node metastasis in endometrial carcinoma: a systematic review and meta-analysis. Oncologist. 2019; 24:e880–90.

97. Falcone F, Normanno N, Losito NS, Scognamiglio G, Esposito Abate R, Chicchinelli N, et al. Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: outcomes from an institutional series. Eur J Obstet Gynecol Reprod Biol. 2019; 240:220–5.

98. Lee TY, Martinez-Outschoorn UE, Schilder RJ, Kim CH, Richard SD, Rosenblum NG, et al. Metformin as a therapeutic target in endometrial cancers. Front Oncol. 2018; 8:341.

99. Kim MK, Seong SJ, Kang SB, Bae DS, Kim JW, Nam JH, et al. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study. J Gynecol Oncol. 2019; 30:e47.

100. Colombo N, Creutzberg C, Querleu D, Barahona M, Sessa C; ESMO Guidelines Committee. Appendix 5: endometrial cancer: eUpdate published online 8 June 2017 (www.esmo.org/Guidelines/Gynaecological-Cancers). Ann Oncol. 2017; 28:iv153–6.

101. Yamagami W, Mikami M, Nagase S, Tabata T, Kobayashi Y, Kaneuchi M, et al. Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms. J Gynecol Oncol. 2020; 31:e18.

102. Lee SW, Lee TS, Hong DG, No JH, Park DC, Bae JM, et al. Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology consensus statement. J Gynecol Oncol. 2017; 28:e12.

103. Kong TW, Ryu HS, Kim SC, Enomoto T, Li J, Kim KH, et al. Asian Society of Gynecologic Oncology International Workshop 2018. J Gynecol Oncol. 2019; 30:e39.